Parkwalk are delighted to announce an investment in Orthox as part of a $12.5m (£9.2m) Series A round for clinical trials of Knee Cartilage Repair FibroFix™ product platform. Parkwalk led the round, joined by existing shareholders OIC/OTIF and Perivoli Innovations, as well as new investors.
Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, announces the completion of a further $4.3m (£3.2m) to close its $12.5m (£9.2m) Series A financing round. The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary.
The current financing was led by Parkwalk, the UK’s most active investor in the university spin-out sector, joined by existing shareholders including OIC/OTIF and Perivoli Innovations. Recent new investors include Additio Investment Group and an undisclosed Chinese strategic investor.
Nick Skaer, co-founder and CEO of Orthox said:
“This $12.5m Series A financing round from a range of high quality medtech investors reflects the strong progress we are making with our award winning FibroFix product platform. FibroFix is unique in emulating the functional properties of cartilage while also facilitating rapid tissue regeneration in patients suffering the debilitating effects of serious knee cartilage injuries. With our approach there is significant bone sparing and strong tissue integration of the implant, which will result in much faster patient recovery from surgery.”
The pivotal clinical trial is expected to open for recruitment later this year with a first cohort of six patients and six months follow up. This will demonstrate initial safety following which the trial will be expanded to 75 patients with two years of follow up. The Company has also submitted a regulatory dossier to the Hungarian medical device regulatory authority, OGYÉI, and is planning clinical trials sites in Budapest and additional leading European Hospitals.
Neil Cameron, Investment Director, Parkwalk commented:
“We see tremendous potential in Orthox’s product platform FibroFix to enable people with orthopaedic injuries to quickly bounce back into doing everyday life activities. Tissue regeneration to treat major cartilage defects is projected to be a $7bn market by 2024. We also see specific value in supporting athletes rapidly returning to form following sports injuries.”
Rajnesh Airey, Additio Investment Group commented:
“What attracted us to invest in Orthox is the medical technology experience of Nick and his team, and their laser focus on developing the company’s unique approach to knee repair, FibroFix. Not only does FibroFix offer swift surgery and recovery, but it is minimally invasive, and nurtures the body’s innate capacity to heal itself. That’s a winning proposition to take into new clinical trials this year.”
FibroFix™ is targeted at treating injuries to the articular cartilage in the knee which covers the ends of the femur (thigh bone) and tibia (shin bone). It protects the surface of these bones and allows the joint to operate smoothly. Around 900,000 patients a year in the US suffer from traumatic, often sports-related, injuries to articular cartilage in the knee. These injuries are inadequately served by current procedures, typically debridement (trimming away the damaged tissue), and/or microfracture (punching holes in the subchondral bone, to allow bleeding and formation of scar and fibrous tissue). Knee cartilage damage can lead to osteoarthritis, which resulted in over 1.3 million total knee replacements in the US and EU in 2011.
